Unicycive Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Unicycive Therapeutics, a clinical stage biotechnology firm focused on kidney disease therapies, announced that CEO Shalabh Gupta will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. A webcast link will be available on the Unicycive website's Investors section on September 13, with an archive accessible for three months. Unicycive's lead drug, Renazorb, targets hyperphosphatemia, while UNI-494 is in late preclinical development for acute kidney injury. For further details, visit www.unicycive.com.

LOS ALTOS, Calif., Sept. 7, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. 

A link to the webcast will be available on September 13, 2021 and may be accessed on the Unicycive website under the Investors section:Events and Presentations. An archive of the webcast will be available for three months.

About Unicycive

Unicycive is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com.

Contacts:

Remy Bernarda
ir@unicycive.com
(650) 900-5470

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/unicycive-therapeutics-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301369986.html

SOURCE Unicycive Therapeutics Inc.

FAQ

When will Unicycive Therapeutics present at the H.C. Wainwright conference?

Unicycive Therapeutics will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

Who is presenting for Unicycive Therapeutics at the conference?

CEO Shalabh Gupta will present an overview of Unicycive Therapeutics at the conference.

Where can I access the Unicycive Therapeutics conference presentation?

The presentation can be accessed via a webcast link available on the Unicycive website's Investors section starting September 13, 2021.

What is the focus of Unicycive Therapeutics?

Unicycive Therapeutics focuses on developing therapies for kidney diseases, including their lead drug Renazorb for hyperphosphatemia.

What is UNI-494 developed by Unicycive Therapeutics?

UNI-494 is a patent-protected drug in late preclinical development for treating acute kidney injury.